According to a literature survey, The total age-adjusted annual incidence rate was 60/100,000, with the highest incidence in the first year of life 120 to 135 per 100,000, Focal epilepsies or epileptic syn-dromes 35 to 40 per 100,000population. The generalized incidence rate is 24/100,000 and 3% incidence rate, 2/100,000 of the epilepsies or epileptic syndromes. The rate of idiopathic EE is 29 per 100,000 and symptomatic or cryptogenic epilepsies is 30/ 100,000.
Comprehensive insight on patient segmentation based on age, sex, classification (Neonatal period, Infancy, Childhood & Others), seizure types (Tonic, Focal, Myoclonic, and others), Biomarker segmentation (SCN1A, SCN2A, SCN3A, and SCN8A )Signs & Symptoms, Clini-cal Manifestations, Treatment types (Opiates, Anticonvulsant medications, Antidepressants, and others) has been provided into the epidemiology section of the Epileptic Encephalopathy(EE) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Bial – Portela C S.A., Marinus Pharmaceuticals, Xenon Pharmaceuticals Inc., MGC Pharmaceuticals d.o.o, UCB Pharma, Abbott, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., GlaxoSmithKline, GW Research Ltd, Stoke Therapeutics, Inc,
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,